Table 4. UV analysis of the combined biomarkers for PFS and OS in 20 bmCRPC-patients on Enzalutamide-therapy.
| Variables | PFS | OS | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| ALP-bouncing AND LDH-normalization AND PSA-decline | 0.23 (0.1–0.7) | 0.01 | 0.26 (0.1–0.8) | 0.02 | |
| PSA-decline alone | 4.4 (1.4–13.4) | 0.01 | 3.8 (1.3–11.5) | 0.02 | |
UV, univariate; PFS, progression-free survival; OS, overall survival; bmCRPC, bone metastatic castration-resistant prostate cancer; HR, hazard ratio; CI, confidence interval; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; PSA, prostate-specific antigen.